GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anatara Lifesciences Ltd (ASX:ANR) » Definitions » Debt-to-Asset

Anatara Lifesciences (ASX:ANR) Debt-to-Asset : 0.00 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Anatara Lifesciences Debt-to-Asset?

Anatara Lifesciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Anatara Lifesciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil. Anatara Lifesciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was A$1.43 Mil. Anatara Lifesciences's debt to asset for the quarter that ended in Dec. 2023 was 0.00.


Anatara Lifesciences Debt-to-Asset Historical Data

The historical data trend for Anatara Lifesciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anatara Lifesciences Debt-to-Asset Chart

Anatara Lifesciences Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only - - 0.02 0.04 -

Anatara Lifesciences Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.04 0.03 - -

Competitive Comparison of Anatara Lifesciences's Debt-to-Asset

For the Biotechnology subindustry, Anatara Lifesciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anatara Lifesciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anatara Lifesciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Anatara Lifesciences's Debt-to-Asset falls into.



Anatara Lifesciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Anatara Lifesciences's Debt-to-Asset for the fiscal year that ended in Jun. 2023 is calculated as

Anatara Lifesciences's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anatara Lifesciences  (ASX:ANR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Anatara Lifesciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Anatara Lifesciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Anatara Lifesciences (ASX:ANR) Business Description

Traded in Other Exchanges
N/A
Address
c/- Perks, 81 Flinders Street, Level 8, Adelaide, SA, AUS, 5000
Anatara Lifesciences Ltd is developing non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. Its products include the Gastrointestinal ReProgramming dietary supplement (GaRP) for humans and Detach for animals. It generates its income from license revenue.

Anatara Lifesciences (ASX:ANR) Headlines

No Headlines